Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 5 | -$0.32 | -$0.15 | -$0.24 |
| Q2 2026 | 6 | -$0.44 | -$0.30 | -$0.38 |
| Q3 2026 | 5 | -$3.63 | $2.49 | -$0.11 |
| Q4 2026 | 3 | -$0.13 | -$0.02 | -$0.07 |
| Q1 2027 | 3 | -$0.59 | -$0.09 | -$0.32 |
| Q2 2027 | 3 | -$0.42 | -$0.06 | -$0.23 |
| Q3 2027 | 3 | $0.12 | $0.84 | $0.45 |
| Q4 2027 | 3 | $0.04 | $0.25 | $0.14 |
Novavax, Inc. last posted its earnings results on Thursday, August 6th, 2026. The company reported $-0.32 earnings per share for the quarter, topping analysts' consensus estimates of $-0.37984 by $0.05984. The company had revenue of 56.70 M for the quarter and had revenue of 1.12 B for the year. Novavax, Inc. has generated $3 earnings per share over the last year ($2.54 diluted earnings per share) and currently has a price-to-earnings ratio of -5.23. Novavax, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/06/2026 | Q2 2026 | -$0.38 | -$0.32 | 0.06 | $52.51 M | $56.70 M |
| 05/06/2026 | Q1 2026 | -$0.25 | -$0.06 | 0.19 | $79.81 M | $139.51 M |
| 02/26/2026 | Q4 2025 | -$0.66 | $0.11 | 0.77 | $89.85 M | $147.14 M |
| 11/06/2025 | Q3 2025 | -$1.08 | -$1.25 | -0.17 | $42.13 M | $70.45 M |
| 08/06/2025 | Q2 2025 | -$0.07 | $0.66 | 0.73 | $152.61 M | $239.24 M |
| 05/08/2025 | Q1 2025 | $0.71 | $3.22 | 2.51 | $343.85 M | $666.66 M |
| 02/27/2025 | Q4 2024 | -$0.75 | -$0.51 | 0.24 | $84.38 M | $88.31 M |
| 11/12/2024 | Q3 2024 | -$0.87 | -$0.76 | 0.11 | $73.78 M | $84.51 M |
| 08/08/2024 | Q2 2024 | $1.64 | $1.11 | -0.53 | $458.58 M | $415.48 M |
| 05/10/2024 | Q1 2024 | -$1.04 | -$1.05 | -0.01 | $101.16 M | $93.86 M |
| 02/28/2024 | Q4 2023 | -$0.49 | -$1.44 | -0.95 | N/A | $291.34 M |
| 11/09/2023 | Q3 2023 | -$1.82 | -$1.26 | 0.56 | N/A | $22.06 M |
| 08/08/2023 | Q2 2023 | -$1.39 | $0.65 | 2.04 | N/A | $424.43 M |
| 05/09/2023 | Q1 2023 | -$3.38 | -$3.41 | -0.03 | N/A | $-6,428,000 |
| 02/28/2023 | Q4 2022 | -$0.92 | -$2.28 | -1.36 | N/A | $287.83 M |
| 11/09/2022 | Q3 2022 | N/A | -$2.15 | N/A | N/A | $734.58 M |
| 08/08/2022 | Q2 2022 | N/A | -$6.53 | N/A | N/A | $185.93 M |
| 05/09/2022 | Q1 2022 | N/A | $2.56 | N/A | N/A | $604.67 M |
| 02/28/2022 | Q4 2021 | N/A | -$11.33 | N/A | N/A | $-726,509,000 |
| 11/04/2021 | Q3 2021 | N/A | -$4.31 | N/A | N/A | $178.84 M |
In the previous quarter, Novavax, Inc. (:NVAX) reported $-0.32 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.37984 by $0.05984.
The conference call for Novavax, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Novavax, Inc.'s latest earnings report can be read online.
Novavax, Inc. (:NVAX) has a recorded annual revenue of $1.12 B.
Novavax, Inc. (:NVAX) has a recorded net income of $440.30 M.Novavax, Inc. has generated $2.72 earnings per share over the last four quarters.
Novavax, Inc. (:NVAX) has a price-to-earnings ratio of -5.23 and price/earnings-to-growth ratio is 0.06.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED